HK1098482A1 - Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same - Google Patents

Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same

Info

Publication number
HK1098482A1
HK1098482A1 HK07105964.4A HK07105964A HK1098482A1 HK 1098482 A1 HK1098482 A1 HK 1098482A1 HK 07105964 A HK07105964 A HK 07105964A HK 1098482 A1 HK1098482 A1 HK 1098482A1
Authority
HK
Hong Kong
Prior art keywords
same
hydrate
pharmaceutical composition
composition containing
crystalline clopidogrel
Prior art date
Application number
HK07105964.4A
Other languages
English (en)
Inventor
Sangmin Yun
Eun Sook Kim
Hee Seock Kim
Bo Sung Kwon
Cheol Kyung Kim
Han Kyong Kim
Kwee-Hyun Suh
Gwan Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020040041309A external-priority patent/KR100563455B1/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of HK1098482A1 publication Critical patent/HK1098482A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK07105964.4A 2004-04-09 2007-06-06 Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same HK1098482A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20040024361 2004-04-09
KR1020040041309A KR100563455B1 (ko) 2004-04-09 2004-06-07 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
PCT/KR2004/002665 WO2005097804A1 (en) 2004-04-09 2004-10-18 Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same

Publications (1)

Publication Number Publication Date
HK1098482A1 true HK1098482A1 (en) 2007-07-20

Family

ID=35061381

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07105964.4A HK1098482A1 (en) 2004-04-09 2007-06-06 Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same

Country Status (13)

Country Link
US (1) US7470707B2 (xx)
EP (2) EP2386560A1 (xx)
JP (1) JP4550884B2 (xx)
CN (1) CN1938319B (xx)
AU (1) AU2004318214B2 (xx)
BR (1) BRPI0418726A (xx)
CA (1) CA2562532C (xx)
HK (1) HK1098482A1 (xx)
IL (1) IL177806A0 (xx)
NO (1) NO20065144L (xx)
NZ (1) NZ551153A (xx)
RU (1) RU2328501C1 (xx)
WO (1) WO2005097804A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8907090B2 (en) * 2003-11-03 2014-12-09 Cadila Healthcare Limited Processes for preparing different forms of (S)-(+)-Clopidogrel bisulfate
GB0418580D0 (en) * 2004-08-21 2004-09-22 Ivax Pharmaceuticals Sro Clopidogrel salt
IS2385B (is) * 2006-02-10 2008-07-15 Actavis Group Hf. Klópidógrel bísúlfat lyfjasamsetningar
KR100945062B1 (ko) 2006-03-22 2010-03-05 한미약품 주식회사 클로피도그렐 1,5-나프탈렌디술폰산염 및 이의 수화물의제조방법
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
KR20160033792A (ko) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
EP2107061A1 (en) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
EP2429291B1 (en) 2009-05-13 2016-07-06 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN111620795B (zh) * 2020-04-27 2021-11-19 华东师范大学 芳基、烷基磺酸类化合物及采用无机硫盐的构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
JP2815691B2 (ja) * 1990-09-20 1998-10-27 麒麟麦酒株式会社 Ｋｒｎ２３９１酸付加塩およびその用途
US6133244A (en) * 1993-10-22 2000-10-17 Institut Pasteur Method for immunization against hepatitis B
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
ATE349451T1 (de) 2001-01-24 2007-01-15 Cadila Healthcare Ltd Verfahren zur herstellung von clopidogrel
IL162461A0 (en) * 2001-12-18 2005-11-20 Teva Pharma Polymorphs of clopidogrel hydrogensulfate
HUP0200438A3 (en) * 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
CZ297472B6 (cs) * 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
GB2393181A (en) * 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
US20070249660A1 (en) * 2004-02-24 2007-10-25 Weber Beat T Pharmacologically Acceptable Salts of Clopidogrel
UA84335C2 (ru) * 2004-04-20 2008-10-10 Санофи Авентис Клопидогрель и его полиморфные формы

Also Published As

Publication number Publication date
EP1732932A4 (en) 2010-04-21
EP1732932A1 (en) 2006-12-20
AU2004318214B2 (en) 2007-12-06
EP1732932B1 (en) 2012-03-21
CA2562532C (en) 2010-02-16
JP4550884B2 (ja) 2010-09-22
BRPI0418726A (pt) 2007-09-11
CN1938319B (zh) 2010-05-12
WO2005097804A1 (en) 2005-10-20
CA2562532A1 (en) 2005-10-20
AU2004318214A1 (en) 2005-10-20
US20050228012A1 (en) 2005-10-13
JP2007532530A (ja) 2007-11-15
NO20065144L (no) 2007-01-08
EP2386560A1 (en) 2011-11-16
CN1938319A (zh) 2007-03-28
RU2328501C1 (ru) 2008-07-10
IL177806A0 (en) 2006-12-31
NZ551153A (en) 2009-10-30
US7470707B2 (en) 2008-12-30

Similar Documents

Publication Publication Date Title
HK1098482A1 (en) Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
AP2064A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
HK1095146A1 (en) Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
EP1984370A4 (en) PROTEIN KINASE ACTIVITY INHIBITING IMIDAZOPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
EP2114904A4 (en) TRIAZOLE DERIVATIVES WITH ANTIPILY EFFECT, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
HK1123789A1 (en) Azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
IL186523A0 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
IL185353A0 (en) Azabicycloalkane derivatives , pharmaceutical compositions containing the same and methods for the preparation thereof
EP1590333A4 (en) GLYCOGENE SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR PREPARING THE SAME
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
HK1112916A1 (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof 3-
IL184314A0 (en) Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
IL186062A0 (en) Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
ZA200804492B (en) S-Omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
ZA200700397B (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
IL179076A0 (en) Azasugasr derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof
PL1655030T3 (pl) Pochodne benzotiadiazyny, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
EP2035406A4 (en) NEW SUBSTITUTED 1H-CHINAZOLIN-2,4-DION DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
EP2144896A4 (en) CRYSTALLINE BEPOTASTIN METAL SALT HYDRATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID HYDRATE
IL192963A0 (en) Rimonabant monohydrate, process for the preparation thereof and pharmaceutical compositions containing same
IL190709A0 (en) 5-omeprazole strontium or a hydrate thereof, methods for preparing the same and pharmaceutical compositions containing the same
ZA200706249B (en) Novel heterocyclic oxime derivatives, method for preparing same and pharmaceutical compositions containing same
IL180870A0 (en) Method for preparing n-aminopiperedine and its salts
AU2004905892A0 (en) Salts and process for preparing same

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131018